“ Parkinson’s Disease Treatment Market by Drug Class (Carbidopa / Levodopa, Dopamine Receptor Agonists, MAO Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) – Global Forecast to 2022″
The Parkinsons disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%.
The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research.
Browse 66 Market Data Tables
33 figures
113 Pages and in-depth TOC on Parkinson ’s Disease Treatment Market https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html Early buyers will receive 10% customization on reports.
By drug class, the carbidopa / levodopa segment is estimated to dominate the market in 2017
The Parkinson’s disease therapeutic drugs market is segmented into carbidopa / levodopa, dopamine receptor agonists, MAO inhibitors, COMT inhibitors, anticholinergics, and other drugs. In 2017, the carbidopa / levodopa segment is expected to account for the largest share of the market. Carbidopa / levodopa drugs are more widely used in the treatment of Parkinson’s disease.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247
By distribution channel, the hospital pharmacies segment is estimated to hold the largest share of the market in 2017
By distribution channel, the Parkinson’s disease therapeutic drugs market has been segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment is expected to account for the largest share of the market. The large share of this segment is primarily attributed to the availability of a wide range of drugs in these facilities and the increasing number of patient visits to hospitals.
H ospitals to dominate the Parkinson’s disease treatment market during the forecast period
The Parkinsons disease treatment is classified by patient care in hospitals and clinics. In 2017, the hospital segment is expected to grow at the fastest rate as compared to the clinical segment. This market is predominantly driven by the availability of robust healthcare services in hospitals and the presence of skilled neurologists in hospitals.
Asia to offer lucrative growth opportunities
By region, the global Parkinson’s disease treatment market is segmented into North America, Europe, Asia, and the rest of the world (RoW). While Europe is expected to grow to the highest share of the market in 2017, Asia is expected to grow to the highest CAGR during the forecast period. The increasing growth of this regional segment is becoming increasingly important.
Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US) , Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
Speak To Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=47265247
Target Audience:
- Parkinson’s disease treatment product manufacturers
- Parkinson’s disease treatment dealers and suppliers
- Human identification service providers
- Parkinson’s disease associations
- Academic institutions
- Venture capitalists
- Consulting firms
- Government bodies